Key result
GLP-1 receptor agonist study on worsening mental illness provides no clinical results.
Why the study?
Does GLP-1 receptor agonist use prevent worsening mental illness in people with depression and anxiety?
Does GLP-1 receptor agonist use prevent worsening mental illness in people with depression and anxiety?
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Should not yet change practice in depression or anxiety; leaves open potential mental health benefits of GLP-1RA pending randomized trials.
BACKGROUND: People with diabetes have an elevated risk of developing depression, anxiety, and suicide. GLP-1 receptor agonists are licensed to treat diabetes and obesity, but data on whether these medications alleviate or exacerbate anxiety, depression, and self-harm are mixed. We studied the risk of worsening mental illness in people already diagnosed with depression, anxiety, or both who were prescribed antidiabetic medications including GLP-1 receptor agonists. METHODS: The study cohort, identified from national Swedish electronic health registers, included people with a diagnosis of depression or anxiety disorder who used any antidiabetic medication between the years 2009 and 2022. GLP-1 receptor agonists, individually and as a group, were compared with non-use of GLP-1 receptor agonists and directly with other second-line antidiabetic medications. A within-individual design was used for all comparisons to reduce confounding, comparing periods of use versus periods of non-use of a medication in the same individual. The primary outcome was worsening of mental illness, defined as a composite of psychiatric hospitalisation; sick leave from work for more than 14 days for psychiatric reasons; hospitalisation due to self-harm; or death by suicide. Secondary outcomes were worsening of depression or anxiety, analysed separately, worsening of substance use disorder, and self-harm. Within-individual stratified Cox models with adjusted hazard ratios (aHRs) and 95% CIs were used. A person with related lived experience was involved in the design and write-up of this study. FINDINGS: The cohort included 95 490 people (56 976 [59·7%] female and 38 514 [40·3%] male) with a mean age of 50·6 years (SD 12·3). Ethnicity data were not available. GLP-1 receptor agonists were used by 22 480 individuals during the follow-up period. Compared with non-use of GLP-1 receptor agonists, semaglutide (aHR 0·58 [95% CI 0·51-0·65]) and liraglutide (0·82 [0·76-0·89]) were associated with lower risk of worsening mental illness, whereas exenatide (1·01 [0·69-1·46]) and dulaglutide (1·01 [0·85-1·20]) were not. Semaglutide was associated with a decreased risk of worsening depression (0·56 [0·44-0·71]), of worsening anxiety (0·62 [0·52-0·73]), and of worsening substance use disorder (0·53 [0·35-0·80]). Liraglutide was associated only with lower risk of worsening depression (0·74 [0·64-0·87]). GLP-1 receptor agonists as a group were associated with a reduced risk of self-harm (0·56 [0·34-0·92]). INTERPRETATION: For anxiety and depression that co-occur with diabetes and obesity, semaglutide and, to a lesser extent, liraglutide might be useful dually effective therapeutic options. Randomised controlled trials evaluating these findings are warranted.
Taipale et al. (2026) studied this question. GLP-1 receptor agonist use was investigated for its association with worsening mental illness in people with depression and anxiety, but the abstract provides no clinical results.
Synapse has enriched 10 related papers. Consider them for comparative context: